This study will examine the quality of life of patients undergoing bone marrow
transplantation to treat a blood disease. It will look at how this therapy affects many
areas of life, including for example, personal relationships, work, and general emotional
state. The information gained may lead to improved ways of dealing with problems that may
arise before or during treatment.
Patients receiving bone marrow stem cells donated by a family member may participate in this
study. They will be interviewed before treatment begins and will complete questionnaires at
the following intervals:
1. day of admission to the hospital
2. day of the transplant
3. 30 days after the transplant
4. 100 days after the transplant
5. 1 year after therapy
6. 2 years after therapy
All questionnaires to be completed after discharge from the hospital will be scheduled
during a regular follow-up visit. Each questionnaire takes about 15 to 20 minutes to
complete. The information provided is confidential and will not be shared.
Clinical research in blood stem cell and bone marrow transplantation documents improvements
in disease free intervals, disease free survival, and the severity of treatment related
toxicities. However, it is important for patients and families to know the quality of life
(QOL) they can expect following an allogeneic transplant. In this longitudinal study we
will compare the QOL of patients undergoing a non-myeloablative allogeneic peripheral blood
stem cell transplant (A-PBSCT) prospectively with that of a myeloablative A-PBSCT. Subjects
(n=106) over the age of 18 will be enrolled. Measures of quality of life (Medical Outcomes
Study Short Form-MOS SF-36 and Functional Assessment of Cancer Therapy-General and Bone
Marrow Transplant - FACT-G and FACT-G/BMT) and symptom distress (Symptom Distress Scale -
SDS) will be administered prior to transplant (baseline) and at set interval post
transplant. Data will be analyzed using repeated measures analysis of variance and
Male or female subjects 18 years of age or older.
Able to read English or Spanish.
Hematological disease requiring A-PBSCT.
Signed informed consent for QOL study.